HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Borzak, S. Search for Related Content PubMed Articles by Borzak, S.

Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy

Clinical impact ratings Internal medicine Cardiology

Key Words: fibrinolytic agents • heparin • myocardial infarction • platelet aggregation inhibitors

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial (Clopidogrel as Adjunctive Reperfusion Therapy [CLARITY]–Thrombolysis in Myocardial Infarction [TIMI] 28 Study).

Allocation: concealed.^*

Blinding: blinded (patients and healthcare providers).^*

Follow up period: to the start of coronary angiography (median 3.5 d), or in patients not having angiography, to hospital discharge or day 8, whichever came first.

Setting: 319 sites in 23 countries.

Patients: 3491 patients who were 18–75 years (mean age 57 y, 80% men); presented within 12 hours after the onset of ischaemic discomfort at rest lasting >20 minutes; had ST segment elevation of 0.1 mV in 2 contiguous limb leads, ST segment elevation of 0.2 mV in 2 contiguous precordial leads, or left bundle branch block that was not known to be old; and were scheduled to receive a fibrinolytic agent, aspirin, and heparin if a fibrin specific lytic agent was prescribed. Exclusion criteria included clopidogrel use in the previous 7 days, planned . . . [Full text of this article]

Steven Borzak, MD

Florida Cardiovascular Research, LC
Atlantis, Florida, USA